Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

B Tran; JM Ruiz-Morales; E Gonzalez-Billalabeitia; A Patrikidou; E Amir; C Seidel; C Bokemeyer; C Fankhauser; T Hermanns; A Rumyantsev; A Tryakin; M Brito; A Fléchon; EM Kwan; T Cheng; D Castellano; X Garcia del Muro; AA Hamid; M Ottaviano; G Palmieri; R Kitson; A Reid; DYC Heng; PL Bedard

Journal article

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

B Tran, JM Ruiz-Morales, E Gonzalez-Billalabeitia, A Patrikidou, E Amir, C Seidel, C Bokemeyer, C Fankhauser, T Hermanns, A Rumyantsev, A Tryakin, M Brito, A Fléchon, EM Kwan, T Cheng, D Castellano, X Garcia del Muro, AA Hamid, M Ottaviano, G Palmieri Show all

Cancer Medicine | WILEY | Published : 2020

DOI: 10.1002/cam4.2674

Open access

Download PDF

Abstract

Background: Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population. Methods: Data were collected from mGCT patients receiving first-line platinum-based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long-axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed. Results: Data from 1135..

View full abstract